



PRESS RELEASE:

LATITUDE Pharmaceuticals Hires Senior Director of Business Development

SAN DIEGO – December 1, 2015 - **LATITUDE Pharmaceuticals, Inc. (LPI)**, a San Diego-based drug formulation developer, announced today that Matthew Singer, PhD, has joined their leadership team as the Senior Director of Business Development. Matt will drive **LPI's** CRO business, as well as licensing and the creation of intellectual property to further **LPI's** position as an industry leader in the formulation for difficult (e.g., insoluble and/or unstable) drugs and drug delivery systems.

Matt brings to **LPI** over 20 years of experience in the life sciences, including more than 15 years in the pharmaceutical and reagent industries. He comes to **LPI** after recently holding senior management positions at Allele Biotechnology & Pharmaceuticals, Inc. and Stemgent Inc., where he led the development of technology partnerships and licensing efforts for pharmaceutical drug discovery.

*"We are very happy to have Matt join **LATITUDE**,"* noted Andrew Chen, PhD, **LPI's** president. *"We expect him to have a strong impact on securing new client business and the out-licensing of our proprietary drug technology platforms and products."*

About LATITUDE Pharmaceuticals, Inc.

LPI is a drug delivery company that develops new intellectual property for the biotech and pharmaceutical industries through IP-driven, leading-edge drug formulation approaches and technologies. **LPI** has built a solid reputation as an innovator and for its successful track record in formulating difficult and/or highly insoluble drug molecules.

For more information, please visit the company's website at www.latituedeprhama.com or send inquiry to info@latituedeprhama.com.